Meeting
2023 ASCO Annual Meeting
A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2–positive breast cancer.
Authors
Hyo S. Han
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Hyo S. Han , Robert Wesolowski , Carla Fisher , Shipra Gandhi , William R Gwin III, Maria J Kowzun , Keerthi Gogineni , Hien Liu , Ricardo L Costa , Julian Guerrero , Stephy Mathew , Michael J. Schell , Hatem Hussein Soliman , Mary L. Disis , Brian J. Czerniecki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT03384914
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 532)
DOI
10.1200/JCO.2023.41.16_suppl.532
Abstract #
532
Poster Bd #
362
Abstract Disclosures
Similar Posters
First Author: Nicholas Patrick McAndrew
Poster
2015 ASCO Annual Meeting
Final pre-specified analysis of the phase II trial of the AE37+GM-CSF vaccine in high risk breast cancer patients to prevent recurrence.
First Author: Julia M. Greene
Poster
2014 ASCO Annual Meeting
A phase II study with lead-in safety cohort of cabazitaxel (C) plus lapatinib (L) as therapy for HER2+ metastatic breast cancer (MBC) with intracranial metastases (mets).
First Author: Denise A. Yardley
Poster
2023 ASCO Annual Meeting
A phase II study of concurrent WOKVAC vaccination with neoadjuvant chemotherapy and HER2-targeted monoclonal antibody therapy.
First Author: William R Gwin III